Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $370.86

United Therapeutics Co. (NASDAQ:UTHR) has been assigned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $370.86.

Several equities analysts have issued reports on UTHR shares. LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group increased their price objective on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday.

United Therapeutics Stock Down 1.3 %

Shares of UTHR stock opened at $352.84 on Monday. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $417.82. The stock’s fifty day simple moving average is $370.07 and its 200 day simple moving average is $349.90. The firm has a market capitalization of $15.75 billion, a P/E ratio of 15.50, a P/E/G ratio of 1.05 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.38 earnings per share. As a group, equities research analysts expect that United Therapeutics will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Christopher Causey sold 510 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 7,800 shares of United Therapeutics stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the sale, the chief financial officer now directly owns 6,978 shares of the company’s stock, valued at approximately $2,442,300. The trade was a 52.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 150,216 shares of company stock valued at $56,269,811 over the last ninety days. 11.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. LSV Asset Management lifted its position in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after acquiring an additional 436,851 shares in the last quarter. World Investment Advisors LLC bought a new position in shares of United Therapeutics in the third quarter valued at approximately $139,206,000. FMR LLC lifted its holdings in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Assetmark Inc. boosted its position in shares of United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after buying an additional 152,249 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.